Keywords: Corcept Thera, Korlym, Cusing's syndrme, USA, FDA, Novartis, Signifor

FDA approves first Cushing’s syndrome drug, Corcept’s Korlym

Article | 20 February 2012

Print This

Shares of USA-based Corcept Therapeutics (Nasdaq: CORT) leapt 62% to $4.90 in after-hours trading on Friday, when the US Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in